Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: results from an open-label extension study.
Heng MeiXiaofan LiuYan LiHu ZhouYing FengGuangxun GaoPeng ChengRuibin HuangLinhua YangJianda HuMing HouYazhou YaoLi LiuYi WangDepei WuLiansheng ZhangChangcheng ZhengXuliang ShenQi HuJing LiuJie JinJianmin LuoYun ZengSujun GaoXiao-Hui ZhangXin ZhouQingzhi ShiRuixiang XiaXiaobao XieZhongxing JiangLi GaoYuansong BaiYan LiJunye XiongRunzi LiJianjun ZouTing NiuRenchi YangHan YanPublished in: Journal of thrombosis and haemostasis : JTH (2021)
The majority of patients who experienced dose tapering to withdrawal experienced a relapse. Long-term treatment with hetrombopag was effective in increasing and maintaining platelet count within the desired range in Chinese adults with ITP. Hetrombopag was well tolerated.
Keyphrases